Skip to main content
Alkem Laboratories Limited logo

Alkem Laboratories Limited — Investor Relations & Filings

Ticker · ALKEM ISIN · INE540L01014 LEI · 335800GCAE5WIF4PSG69 BSE.NS Manufacturing
Open in API
Filings indexed 1,764 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS ALKEM

About Alkem Laboratories Limited

https://www.alkemlabs.com/

Alkem Laboratories Limited specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company’s portfolio covers a wide range of therapeutic areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients. It has also expanded into chronic therapeutic segments such as cardiology, diabetology, neurology, and dermatology. Alkem operates multiple manufacturing facilities and advanced research and development centers dedicated to formulation development and active pharmaceutical ingredients. The company provides branded generics, generic medications, and active pharmaceutical ingredients to various international markets. Its operations are supported by a robust supply chain and a focus on high-quality production standards to meet global regulatory requirements.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith the details of the Analyst / Investor meeting to be held on 29th May,2026.
Regulatory Filings Classification · 92% confidence The document is a formal notice sent by the company’s Company Secretary to stock exchanges under SEBI Listing Obligations, disclosing the schedule of a one-on-one analyst/institutional investor meeting. It does not contain financial results, presentations, or actual report content; rather, it is a regulatory announcement/compliance filing. This fits the fallback “Regulatory Filings” category.
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 83% confidence The document is a stock exchange intimation under SEBI LODR regulations, notifying the schedule of an analyst/institutional investor meeting. It contains no financial statements, earnings highlights, or actual report content. It is a general regulatory announcement rather than a formal financial report, management presentation, or dividend/board change notice. This fits the Regulatory Filings (RNS) category.
2026-05-25 English
Please find attached herewith Intimation of Conference Call of Q4FY26 and FY26 Financial Result.
Regulatory Filings Classification · 80% confidence The document is a formal notice under SEBI LODR to stock exchanges informing of a conference call on Q4FY26 and FY26 results. It does not contain any financial statements, management discussion, or substantive financial data, nor is it the transcript of the call. It is an announcement of an upcoming event (conference call), which does not fit specific categories like IR (Interim Report), CT (full conference call transcript), ER (earnings release), or IP (investor presentation). Therefore, by the process of elimination and as a general regulatory announcement, it falls under Regulatory Filings (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 88% confidence The document is a formal SEBI LODR regulatory announcement informing exchanges and investors of a scheduled Q4FY26 and FY26 earnings conference call. It does not contain actual financial results (so it is not an Earnings Release or Interim/Annual Report), nor is it a transcript (Call Transcript), proxy, dividend notice, or other specific category. It is a general regulatory announcement of an upcoming investor event. Accordingly, it falls into the fallback “Regulatory Filings” category (RNS).
2026-05-20 English
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve (i) The Standalone and Consolidated ...
Regulatory Filings Classification · 24% confidence The document is a notice to stock exchanges about a scheduled Board of Directors meeting to consider and approve audited financial results and recommend a final dividend. It does not contain the actual financial results, nor is it announcing publication of a report or a management change; it is a generic regulatory announcement under SEBI listing rules. This falls under the miscellaneous regulatory filings category (RNS).
2026-05-19 English
General Updates
Board/Management Information Classification · 95% confidence The document is a formal disclosure under SEBI LODR Regulation 30 to stock exchanges announcing the appointment of a senior management person (Mr. Chanakya Misra), including details in an annexure. It is an announcement of a change in senior management, fitting the Board/Management Information category.
2026-05-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.